Form 4: Alkermes EVP Exercises Stock Options and Receives Restricted Stock Units

Craig C. Hopkinson, EVP R&D and Chief Medical Officer of Alkermes plc, reports transactions involving ordinary shares and derivative securities, including the exercise of restricted stock units and the grant of new stock options and restricted stock units.

Summary

• On February 18, 2025, Craig C. Hopkinson exercised 8,896 restricted stock units, receiving ordinary shares.
• Also on February 18, 2025, 3,950 ordinary shares were disposed of to cover tax obligations at a price of $35.9 per share.
• Following these transactions, Hopkinson directly owns 62,821 ordinary shares.
• On February 19, 2025, Hopkinson was granted 63,991 employee stock options with an exercise price of $35.84, vesting in four equal annual installments commencing on February 19, 2026, and expiring on February 19, 2035.
• Hopkinson was also granted 30,692 restricted stock units, vesting in four equal annual installments commencing on February 19, 2026.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The transactions are routine and expected, but the grants of new equity could be seen as a positive signal of the company's confidence in its future.

Positives

• The grant of stock options and restricted stock units to a key executive like Hopkinson could be seen as a positive sign, aligning his interests with those of the shareholders and incentivizing him to drive company performance.

Negatives

• The disposal of 3,950 shares to cover tax obligations could be interpreted as a slight negative, although it's a common practice and doesn't necessarily indicate a lack of confidence in the company.

Risks

• The vesting schedules of the stock options and restricted stock units mean that the full benefit to Hopkinson, and therefore the full alignment of his interests, is contingent on his continued employment with Alkermes over the next several years.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting schedules of the stock options and restricted stock units suggest an expectation of continued employment and contribution from the executive.

Industry Context

Stock option and restricted stock unit grants are common practices in the pharmaceutical industry to incentivize and retain key executives. The specific terms of these grants are generally aligned with industry standards and company performance goals.

Comparison to Industry Standards

• Stock option grants and restricted stock units are standard compensation tools in the pharmaceutical industry, used by companies like Amgen, Biogen, and Vertex to align executive interests with shareholder value.
• Vesting schedules of four years are also typical, encouraging long-term commitment from executives.
• The specific number of options and units granted would be benchmarked against peer companies based on factors like company size, executive role, and performance.

Stakeholder Impact

• Shareholders may view the equity grants as a positive sign, aligning management's interests with theirs.
• Employees may see the grants as a sign of the company's commitment to its leadership team.

Key Dates

Keywords

Alkermes, Hopkinson, stock options, restricted stock units, Form 4, insider trading, executive compensation, ALKS